Cargando…

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens

The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. The aim of this study was to investigate the prognostic role of circulating VEGF, PDGF, SDF-1, osteopontin and CEA in patients randomly assigned to three bevacizumab-based regimens. Plasma sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinetti, Antonia, Miceli, Rosalba, Sottotetti, Elisa, Di Bartolomeo, Maria, de Braud, Filippo, Gevorgyan, Arpine, Dotti, Katia Fiorella, Bajetta, Emilio, Campiglio, Manuela, Bianchi, Francesca, Bregni, Giacomo, Pietrantonio, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190566/ https://www.ncbi.nlm.nih.gov/pubmed/25256831 http://dx.doi.org/10.3390/cancers6031753

Ejemplares similares

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients
por: Di Salvatore, Mariantonietta, et al.
Publicado: (2017)

Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status
por: Pietrantonio, Filippo, et al.
Publicado: (2014)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
por: Iacovelli, Roberto, et al.
Publicado: (2014)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
por: Pietrantonio, Filippo, et al.
Publicado: (2016)

The Landscape of Actionable Gene Fusions in Colorectal Cancer
por: Pagani, Filippo, et al.
Publicado: (2019)

ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series
por: Ambrosini, Margherita, et al.
Publicado: (2022)

Central venous catheters-related-thrombosis and risk factors in oncological patients: A retrospective evaluation of recent risk scores
por: Taglialatela, Ida, et al.
Publicado: (2022)

Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
por: Celio, Luigi, et al.
Publicado: (2013)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study
por: Fucà, Giovanni, et al.
Publicado: (2019)

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
por: Zilembo, N., et al.
Publicado: (1995)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
por: Cremolini, Chiara, et al.
Publicado: (2018)

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials
por: Modest, Dominik Paul, et al.
Publicado: (2019)

Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
por: Celio, Luigi, et al.
Publicado: (2019)

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

Role of cMET in the Development and Progression of Colorectal Cancer
por: Pérez-Vargas, Juan Carlos Samamé, et al.
Publicado: (2013)

LightSNiP assay is a good strategy for pharmacogenetics test
por: Cheli, Stefania, et al.
Publicado: (2015)

Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies
por: Celio, Luigi, et al.
Publicado: (2015)

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML
por: Sorror, Mohamed L., et al.
Publicado: (2020)

COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study
por: Nichetti, Federico, et al.
Publicado: (2020)

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
por: Cremolini, Chiara, et al.
Publicado: (2017)

Pitfalls in neuroendocrine tumor diagnosis
por: Bajetta, Emilio, et al.
Publicado: (2009)

FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study.
por: Bajetta, E., et al.
Publicado: (1998)

Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
por: Randon, Giovanni, et al.
Publicado: (2023)

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
por: Chen, Clara, et al.
Publicado: (2015)

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF (V600E)-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
por: Tabernero, Josep, et al.
Publicado: (2023)

The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2019)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
por: Lorusso, Domenica, et al.
Publicado: (2020)

Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience
por: Sepe, Pierangela, et al.
Publicado: (2019)

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
por: Kast, Richard E.
Publicado: (2018)

miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
por: Migliore, Cristina, et al.
Publicado: (2018)

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
por: Randon, Giovanni, et al.
Publicado: (2019)

Author response to Colle et al
por: Fucà, Giovanni, et al.
Publicado: (2021)

A female survivor of childhood medulloblastoma presenting with growth-hormone-induced edema and inflammatory lesions: a case report
por: Biassoni, Veronica, et al.
Publicado: (2009)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
por: Salmi, Narimane, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4mpj6jiqourpvoe8ps86ntmjq1